Hemispherian
About edit
Hemispherian AS is a Norwegian clinical-stage pharmaceutical company developing novel small molecule drugs targeting the TET2 enzyme for the treatment of aggressive cancers.
Technology edit
Hemispherian's drug development approach focuses on the TET2 (Ten-Eleven Translocation 2) enzyme — a DNA demethylase that plays a critical role in epigenetic regulation. Dysregulation or mutation of TET2 is implicated in the progression of various aggressive cancers. The company is developing a novel class of small molecules that target TET2 as a therapeutic strategy.
Pipeline edit
Hemispherian is at the clinical-stage, indicating active development toward or within clinical trials. The company has published key publications related to its scientific approach.